Veracyte, Inc. VCYT
We take great care to ensure that the data presented and summarized in this overview for VERACYTE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VCYT
View all-
Vanguard Group Inc Valley Forge, PA8.21MShares$261 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.79MShares$248 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI6.6MShares$210 Million0.42% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.2MShares$134 Million1.46% of portfolio
-
Wellington Management Group LLP Boston, MA4.08MShares$130 Million0.03% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO3.08MShares$97.9 Million1.83% of portfolio
-
State Street Corp Boston, MA2.91MShares$92.5 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$91.6 Million0.03% of portfolio
-
Nikko Asset Management Americas, Inc.2.49MShares$79.2 Million1.1% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.49MShares$79.2 Million0.07% of portfolio
Latest Institutional Activity in VCYT
Top Purchases
Top Sells
About VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Insider Transactions at VCYT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 07
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
7,411
-3.49%
|
$229,741
$31.5 P/Share
|
Mar 06
2025
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,601
+20.17%
|
-
|
Mar 06
2025
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
30,200
+23.1%
|
-
|
Mar 06
2025
|
John Leite Chief Commercial Officer-CLIA |
BUY
Grant, award, or other acquisition
|
Direct |
36,240
+25.18%
|
-
|
Mar 06
2025
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,200
+17.35%
|
-
|
Mar 06
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,160
+18.46%
|
-
|
Mar 06
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,288
+21.08%
|
-
|
Mar 04
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,142
-1.6%
|
$37,686
$33.69 P/Share
|
Mar 04
2025
|
Marc Stapley Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
52,697
-5.73%
|
$1,739,001
$33.7 P/Share
|
Mar 04
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
8,037
-4.54%
|
$265,221
$33.41 P/Share
|
Mar 02
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,255
-10.36%
|
$280,670
$34.76 P/Share
|
Mar 02
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,070
-8.87%
|
$376,380
$34.76 P/Share
|
Mar 02
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,301
-10.55%
|
$146,234
$34.76 P/Share
|
Mar 02
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,754
-6.94%
|
$229,636
$34.76 P/Share
|
Mar 02
2025
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,324
-5.96%
|
$691,016
$34.76 P/Share
|
Mar 02
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
7,650
-9.68%
|
$260,100
$34.76 P/Share
|
Feb 27
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,000
-8.07%
|
$231,000
$33.84 P/Share
|
Feb 27
2025
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
13,466
+13.44%
|
-
|
Feb 27
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,911
-8.71%
|
$393,063
$33.84 P/Share
|
Feb 27
2025
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,170
+14.49%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 472K shares |
---|---|
Exercise of conversion of derivative security | 67.5K shares |
Open market or private sale | 279K shares |
---|---|
Payment of exercise price or tax liability | 175K shares |